SLC25A28: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: SLC25A28

NCBI ID: G81894

SLC25A28

SLC25A28: A Potential Drug Target and Biomarker for Neurological Disorders

SLC25A28 is a member of the Solute Carrier Family 25, which is a well-established transmembrane protein family that plays a crucial role in the transport of various molecules across cell membranes. SLC25A28 is a 28-kDa protein that is expressed in various tissues and organs, including brain, heart, liver, and kidney.

SLC25A28 functions as a carrier protein for a wide range of molecules, including neurotransmitters, hormones, and vitamins. It is specifically designed to transport neurotransmitters across the blood-brain barrier, which is a specialized barrier that selectively allows certain molecules to enter the central nervous system. This function is critical for the proper functioning of the brain and is a key factor in the development and treatment of neurological disorders.

SLC25A28 is also expressed in other tissues and organs that are involved in the regulation of various physiological processes. For example, it is expressed in the liver, where it is involved in the transport of bile acids across the membrane to the bile ducts. It is also expressed in the heart, where it is involved in the transport of ions across the membrane to the cardiac muscle.

SLC25A28 is a glycoprotein, which means that it consists of a protein that is capped with a carbohydrate molecule. This carbohydrate molecule is important for the structure and function of the protein, and it plays a key role in SLC25A28's regulation. The carbohydrate molecule is attached to the protein via a disulfide bond, which is a covalent bond that is formed by the fusion of two amino acids.

SLC25A28 is involved in many different biological processes that are critical for the health and function of the body. For example, it is involved in the regulation of neurotransmitter release from the central nervous system, which is critical for the communication between neurons and the development of various neurological disorders. It is also involved in the regulation of ion transport across cell membranes, which is critical for the proper functioning of various physiological processes.

SLC25A28 is a potential drug target for several reasons. Firstly, it is involved in the regulation of critical physiological processes, which makes it an attractive target for the development of new treatments for various neurological disorders. Secondly, its structure and function are well- conserved, which suggests that it is a good candidate for the development of a small molecule inhibitor that can modulate its activity. Finally, its expression is highly conserved across various tissues and organisms, which suggests that it is a robust and reliable target for drug development.

SLC25A28 is also a potential biomarker for several neurological disorders. For example, it is involved in the regulation of neurotransmitter release from the central nervous system, which is critical for the development and treatment of disorders such as depression, anxiety, and schizophrenia. It is also involved in the regulation of ion transport across cell membranes, which is critical for the proper functioning of various physiological processes. This makes it an attractive target for the development of new diagnostic tests for these disorders.

In conclusion, SLC25A28 is a well-established carrier protein that is involved in the regulation of various physiological processes. Its structure and function are well- conserved, and its expression is highly conserved across various tissues and organisms. These features make it an attractive target for the development of new drugs and diagnostic tests for neurological disorders. Further research is needed to fully understand the role of SLC25A28 in the regulation of physiological processes and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 25 Member 28

Functions: Mitochondrial iron transporter that mediates iron uptake. Probably required for heme synthesis of hemoproteins and Fe-S cluster assembly in non-erythroid cells

The "SLC25A28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets